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Abstract: MicroRNAs (miRNAs) are short non-coding RNAs that are involved in the regulation of
gene expression. Previous reports showed an over-expression of miRNA-21 (miR-21) in various
cancer cells, and its up-regulation is closely related to cancer initiation, proliferation and metastasis.
In this work, we envisioned the development of novel antimiRzymes (anti-miRNA-DNAzyme) that
are capable of selectively targeting and cleaving miR-21 and inhibit its expression in cancer cells using
the DNAzyme technique. For this purpose, we have designed different antimiRzyme candidates
by systematically targeting different regions of miR-21. Our results demonstrated that RNV541,
a potential arm-loop-arm type antimiRzyme, was very efficient (90%) to suppress miR-21 expression
in U87MG malignant glioblastoma cell line at 200 nM concentration. In addition, RNV541 also
inhibited miR-21 expression (50%) in MDA-MB-231 breast cancer cell line. For targeted delivery,
we conjugated RNV541 with a transferrin receptor (TfR) targeting aptamer for TfR-mediated cancer
cell delivery. As expected, the developed chimeric structure efficiently delivered the antimiRzyme
RNV541 into TfR positive glioblastoma cells. TfR aptamer-RNV541 chimeric construct showed 52%
inhibition of miR-21 expression in U87MG glioblastoma cells at 2000 nM concentration, without using
any transfection reagents, making it a highly desirable strategy to tackle miR-21 over-expressed
malignant cancers. Although these are in vitro based observations, based on our results, we firmly
believe that our findings could be beneficial towards the development of targeted cancer therapeutics
where conventional therapies face several challenges.
Keywords: oligonucleotides; DNAzyme; antimiRzyme; miR-21 targeting
1. Introduction
MicroRNAs (miRNAs) are 18–25 nucleotides (nt) long non-protein coding RNAs that are involved
in the regulation of gene expression. Growing evidence in recent years has demonstrated that
tissue-specific expression patterns of miRNAs directly correlate with altered expression profiles of
up to 90% of human gene transcripts [1], and are associated with the development of more than 160
different types of diseases [2] including cancers. Indeed, dysregulation of miRNA has been reported
in the key steps of the cancer development such as initiation, proliferation, immune invasion and
metastasis. Recent in vivo studies demonstrated that restoration of aberrantly expressed miRNAs
could alleviate and even reverse the malignant cancer phenotypes [3]. Over the past decade, a number
of miRNAs have been reported to be dysregulated in human cancers. MiRNA 21 (miR-21) is one of
the most investigated candidates, and which is over-expressed in a variety of cancer cells including
glioma [4], breast cancer [5], hepatocellular carcinoma [6], pancreatic cancer, colorectal cancer [7],
lung cancer, oral cancer [8], and acute myeloid leukemia [9], as well as various cancer stem cells [10].
Importantly, miR-21 has been confirmed to be critical in the maintenance of the malignant phenotype
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of cancer and inversely correlated with patient survival and tumor grading [11–13]. Consequently,
miR-21 has gained significant interest in the development of cancer therapeutics. Various miRNA
targeting strategies have been reported in recent years towards developing novel therapeutic molecules.
Application of antisense oligonucleotide sequences commonly known as antimiRs (or antagomiRs)
or miRNA sponges are some of the common direct methods for miRNA inhibition [14]. However,
recent reports also demonstrated indirect inhibition of miRNA biogenesis using CRISPER (Clustered
Regularly Interspaced Short Palindromic Repeats) system [15] and also by using small molecules [16].
Although these approaches are effective, there are some disadvantages, such as efficacy and tissue
specific delivery, that need to be considered for their clinical translations [16].
DNA enzymes (commonly known as DNAzymes) are a unique class of single-stranded catalytic
oligonucleotide that can specifically target messenger RNAs through Watson–Crick base pairing
interactions and inhibit gene expression [17]. The structure of the DNAzyme includes two binding
arms for target specific mRNA binding, and a catalytic loop connecting the binding arms designed to
cleave the phosphodiester bond in the target RNA mainly at the purine–pyrimidine or, less frequently,
at the purine–purine junction in the presence of divalent metal ions (e.g., Mg2+, Ca2+, Pb2+) [18].
The unique structural properties of DNAzymes ensure the high-specific gene regulation compared with
other gene silencing methods such as siRNA and antisense oligonucleotides [18]. Although DNAzymes
are majorly used to target messenger RNAs, this type of molecule can also be used to target and
inhibit miRNAs. Towards this, Belter et al. reported the inhibition of miRNAs in glioma cells [19].
Compared with other strategies currently used for miRNA inhibition, DNAzyme technology has
certain advantages, such as low production cost for DNA oligonucleotide synthesis, and, importantly,
the target RNA cleavage process is repetitive over several cycles of annealing and catalytic cleavage,
which in theory will require a low concentration of DNAzyme for sustainable therapeutic efficacy [19].
In this study, we envisioned the design and development of novel catalytic oligonucleotides targeting
miR-21 termed antimiRzymes to inhibit their expression in solid cancers, and then developed a
transferrin receptor (TFR) targeting aptamer conjugated antimiRzyme chimera for targeted inhibition
of miR-21 without using any lipid-based transfection reagents.
2. Results
2.1. Rational Design and In Vitro Evaluation of antimiRzymes Targeting miR-21
DNAzymes with “8–17” and “10–23” catalytic motif structures developed by in vitro selection
methodologies are the two widely studied and well-characterized RNA-cleaving DNA molecules [20].
The 10–23 DNAzyme structure cleaves the RNA at any purine–pyrimidine (RY) junction under
physiological conditions, and showed better tolerance to different target sequences [20]. In our studies,
we used this DNAzyme pattern to design novel antimiRzymes specific to miR-21. Santoro et al.
suggested that the highest cleavage efficiency was observed with ‘A:U’ and ‘G:U’ combinations [21].
In line with this, we selected two different ‘A:U’ sites of miR-21-5p sequence for designing antimiRzymes.
As shown in Figure 1, four different DNAzyme sequences, namely, RNV539, RNV540, RNV541 and
RNV542, with varying binding arm lengths at both 5′- and 3′-ends were designed, and each contained
a conserved 15-mer “10–23” catalytic motif. The 5′ and 3′ binding arm sequences were designed to
form Watson–Crick base pairs specific to the mature miR-21target.
Although the designed antimiRzymes share an identical catalytic domain, the miR-21 cleaving
efficacy of individual antimiRzyme sequences could be affected by various other factors such as
targeting affinity, capabilities to adopt the arm-loop-arm structure, and catalytic properties in the
presence of divalent metal ions [20], and this has to be experimentally tested. To determine the catalytic
activity of the antimiRzymes, initially we performed in vitro cleavage experiments by incubating
the antimiRzymes RNV539-RNV542 with a 5′-fluorescent dye (FAM) labelled synthetic miR-21 RNA
template in presence of 10 mM Mg2+ divalent cations at different time points over two hours. The results
demonstrated that both RNV541 and 542 displayed notable miR-21 cleavage in a time-dependent
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manner (Figure 2), whereas RNV539 and RNV540 were not effective in cleaving miR-21 RNA template
as it showed low or no catalytic efficacy. In particular, RNV541 showed 40% cleavage efficiency after
120 min incubation which was almost twice the cleavage rate achieved with RNV542. In line with these
initial results of miR-21 RNA template cleavage, we have used the antimiRzyme RNV541 for further
analyses in miR-21 overexpressed cancer cells, including glioblastoma U87MG and triple negative
breast cancer MDA-MB-231 cells.Molecules 2019, 24, x FOR PEER REVIEW 3 of 11 
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Figure 1. Design of novel “10–23” motif antimiRzymes RNV539, RNV540, RNV541 and RNV542
targeting miR-21. The designed antimiRzymes had a 15 nt catalytic loop and two substrate binding
arms of varying sizes. In this design, the antimiRzymes (black) and its miR-21substrate (blue) is
hybridized via Watson–Crick base pairing and cleavage occurs at the A:U dinucleotide position (red).
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Figure 2. In vitro miR-21 RNA template cleavage assay using the designed synthetic antimiRzymes.
Synthetic miR-21 RNA template was incubated with 100 nM antimiRzymes at 37 ◦C. The reactions
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2.2. Evaluation of miR-21 Cleavage Activity of RNV541 antimiRzymes in Cancer Cell Lines
Following the initial in vitro screening using synthetic miR-21 template, we investigated the
potential of RNV541 to target and cleave miR-21 in cancer cells by transfecting RNV541 in glioblastoma
(U87MG) and breast cancer (MDA-MB-231) cell lines at different concentrations of 100 nM, 200 nM and
400 nM. After 24 h of transfection, the cells were harvested, and total RNA was isolated. The expression
of miR-21 was measured by RT-qPCR. Notably, RNV541 demonstrated remarkable reduction in mi-21
expression in U87MG glioblastoma cells. Specifically, we observed 68% and 90% reduction in miR-21
expression at 100 nM and 200 nM concentrations, respectively (Figure 3). The cleavage efficacy
seemed to have plateaued at 200 nM as no further improvement in cleavage was observed at 400 nM.
In addition, we also observed high inhibition of miR-21 expression in MDA-MB-231 breast cancer cells
after the treatment with RNV541. In the case of MDA-MB-231 cells, a similar dose dependent miR-21
reduction was observed, however, the efficacy of miR-21 inhibition was not as high as observed in
U87MG cells, but moderately high with rates of 32%, 40% and 54% for 100 nM, 200 nM and 400 nM
concentrations, respectively.Molecules 2019, 24, x FOR PEER REVIEW 5 of 11 
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2.3. Evaluation of Transferrin Receptor Aptamer-RNV541 Chimera for Cancer Cell Targeted Inhibition
of miR-21
Targeted delivery is one of the major challenges in oligonucleotide drug development. For high
therapeutic efficacy in vivo, the antimiRzymes need to specifically target and penetrate cancer
cells in high concentration for a sufficient period of time, which remains a significant hurdle for
oligonucleotide-based cancer treatment. Generally, the negative charge of nucleic acid structures
makes them difficult to penetrate or diffuse across the lipid cell membranes [20] in order to recognize
their RNA targets in the cytoplasm. Towards this goal, nucleic acid aptamer technology provides a
great opportunity to circumvent the targeted delivery issue of antimiRzymes. Aptamers are short
single-stranded nucleic acid sequences that can recognize and bind to target molecules with high affinity
and specificity in a way similar to antibodies [22–24]. Various aptamer-mediated drug delivery systems
have been explored in recent years for either small molecule chemotherapeutics [25] or therapeutic
nucleic acids (i.e., siRNA, antisense oligonucleotide, antimiR) [26,27]. In this work, we aimed at
delivering miR-21 into cancer cells by employing a previously developed transferrin receptor (TfR)
aptamer [28].
Although TfR is generally expressed at low levels in different tissues under physiological
conditions [29], TfR over-expression has been observed in different cancer cells [30]. Importantly,
via clathrin-mediated endocytosis, TfR binding aptamers can mediate the traversal of TfR conjugated
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molecules into cancer cells [31], making them a promising target for precision cancer therapy.
As shown in Figure 4, we conjugated the TfR aptamer to RNV541 antimiRzyme via a five consecutive
deoxythymidine nucleotides (-TTTTT-) bridge to construct TfR aptamer-RNV541 chimera. As reported
previously, the TTTTT linker could help retaining the structural conformation of both the TfR aptamer
and the antimiRzyme RNV541 [32]. While the purpose of the aptamer part is to specifically target TfR
and internalize into cancer cells efficiently, the RNV541 antimiRzyme component will recognize and
inhibit the expression of endogenous miR-21 target in the cytoplasm.Molecules 2019, 24, x FOR PEER REVIEW 6 of 11 
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2.4. TfR Aptamer-RNV541 Chimera Effectively Suppressed miR-21 Expression in Glioblastoma Cells
The developed TfR aptamer-RNV541 chimera was then synthesized and tested in the TfR positive
U87MG glioblastoma cells without using any transfection reagents. Our results demonstrated that
the TfR aptamer-RNV541 chimera showed a clear dose-dependent inhibition of miR-21 expression in
U87MG cells (Figure 5). Higher inhibition of miR-21 expression was observed at both 1000 nM (41%
inhibition) and 2000 nM (52% inhibition) treatment groups. However, it should be mentioned that
the unconjugated RNV541 did not show any change in reducing miR-21 expression (data not shown).
These results provide proof-of-principle evidence regarding the rationality of utilizing an aptamer
conjugated antimiRzyme approach for targeted inhibition of miR-21 in malignant glioblastoma cells.
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3. Discussion
Despite the progress in cancer management over the past century, conventional treatments
including surgery, radiation, and chemotherapy still face a number of challenges [33,34]. As a relatively
new field, tumor suppressor miRNAs, such as miR-21, miR-155, miR-10, have demonstrated great
potential in future cancer treatment [35]. Compared with traditional cancer treatment, miRNA-mediated
anti-cancer therapy enables regulation of entire signaling networks within the cells, making them an
interesting option for developing cancer therapeutics [36]. The reported “OncomiR Addiction” depicts
the restoration of certain dysregulated miRNAs capable of abrogating and even reversing the malignant
cancer phenotypes [37]. This is especially true for miR-21, one of the prominent and most investigated
“oncomiRs” [37]. A well-designed recent in vivo study demonstrated complete regression of malignant
lymphoid-like phenotype tumors after the inactivation of miR-21 [37]. Further investigations also
disclosed that miR-21 is expressed in virtually all types of cancer cells and the miR-21 upregulation is
closely correlated with all key steps of cancer development, making it a highly desirable target to tackle
malignant cancers [38]. Previous efforts on catalytic DNA molecules (DNAzymes) mainly focused
on the regulation of messenger RNAs, and recently the potential of DNAzyme was also applied for
miRNA regulation [39]. As DNAzyme-mediated miRNA silencing possesses certain advantages over
traditional miRNA regulation strategies, we investigated the potential of catalytic DNA molecules,
termed antimiRzymes, to target and cleave miR-21, using the established “10–23” arm-loop-arm design
containing a defined 15-mer catalytic core. Since there is no GU position at the purine–pyrimidine
junction at the catalytic cleavage site on the mature miR-21 sequence, two of the available AU points on
miR-21 sequence were used to design four different antimiRzyme candidates named RNV539–RNV542
(Figure 1). By performing an in vitro cleavage assay, we found that only two candidates, RNV541 and
RNV542, targeting the A:U junction at the 3′ end, achieved notable miR-21 cleavage efficacy, of which
RNV541 was found to more effective with 40% cleavage efficacy (Figure 2). As suggested by a previous
study, we speculate that the observed variable efficiencies of different antimiRzyme sequences might
be due to the formation of improper secondary structures ultimately affecting the potential of the
conserved catalytic core region [19].
Inspired by the in vitro cleavage assay, we extended the evaluation of RNV541 in malignant
glioblastoma (U87MG) and breast cancer cells (MDA-MB-231), and the experiment demonstrated that
RNV541 sequence was remarkably effective in inhibiting the expression of miR-21 in U87MG cells
(90%), and also yielded 54% inhibition in MDA-MB-231 cells. As reported previously, a single miRNA
has the ability to target and regulate hundreds of genes [3], and therefore, even small perturbations in
the miRNA network may have an impact on cell phenotype. Taking this into account, antimiRzyme
sequence RNV541, with a 90% miR-21 inhibition rate in cancer cells, may hold great potential to be
developed as a novel anti-cancer therapeutic. However, similar to other nucleic acid-based medicines,
delivery remains a key issue for the systemic administration of antimiRzymes. Although antibodies
have been employed for targeted delivery, their clinical translation is impeded to some extent by
severe side effects and immunogenicity. To overcome this, we used nucleic acid aptamer technology
towards the delivery of antimiRzyme RNV541. To successfully deliver antimiRzyme into cancer cells,
an aptamer not only needs to recognize an appropriate cancer marker, but also requires efficient cell
internalization after target binding [40,41]. The previously developed TfR aptamer represents an ideal
tool for this purpose [42]. TfR is a type of membrane glycoprotein responsible for iron homeostasis [31].
While TfR is ubiquitously expressed at low level in most normal human tissues, highly elevated
expression of TfR is typically associated with rapidly proliferating cells, mainly in cancers [29,30].
This is not surprising given that malignant cells have an intrinsically high demand for iron as a
cofactor for DNA synthesis and cell cycle progression. The significance of TfR in targeted cancer
therapy is supported by several factors: (i) overexpression by cancer cells, (ii) cell surface accessibility
promoted by clathrin/dynamin dependent endocytosis [31], and (iii) an essential role in cell growth
and proliferation. Over the past decades, TfR-based drug delivery systems have been explored for
glioblastoma, breast cancer and Alzheimer’s disease [42,43].
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Similar to previously reported aptamer-therapeutic nucleic acid chimeras [44], a bifunctional
aptamer-antimiRzyme chimera was designed in this study by utilizing a previously reported TfR
aptamer [42] and the newly developed antimiRzyme RNV541. A 5-mer consecutive 2′-deoxy thymidine
nucleotide (-TTTTT-) was used to link the TfR aptamer and the RNV541 antimiRzyme in order
to construct the chimera, which might reduce any possible interaction between the aptamer and
antimiRzymes, and can also maximize the possibility of retaining the functions of both TfR aptamer
and RNV541 (Figure 4). After testing with TfR overexpressed glioblastoma U87MG cells in the absence
of transfection reagents, over 50% miR-21 suppression was recorded, which clearly demonstrates the
efficacy of aptamer-RNV541 chimera. Unlike other therapeutic nucleic acid-based approaches, such as
siRNA, which only interrupts and regulates a particular type of gene, antimiRzyme RNV541-based
inhibition of miR-21 can affect post transcriptional regulation of the miR-21 network by controlling the
expression of hundreds of genes implicated in cancer pathology. This suggests that even small-scale
suppression of the miR-21 expression could result in a significant anti-cancer effect, and the 50% miR-21
suppression rate observed for aptamer-RNV541 chimera without using any transfection reagent is
therefore very promising towards targeted cancer treatment.
4. Materials and Methods
4.1. Oligonucleotide Sequences
All sequences were synthesized by Integrated DNA Technologies (IDT, Singapore, Singapore).
The sequence information of RNV539–542 is shown in Figure 1, and the aptamer-antimiRzyme chimera
is shown in Figure 4 (before treatment, this chimera structure was denatured at 95 ◦C for 5 min and
then snap cooled on ice for 10 min). Both antimiRzymes and aptamer-RNV541 antimiRzyme chimera
sequences were synthesized in house on GE AKTA oligopilot plus 10 oligonucleotide synthesizer (GE
Healthcare Life Sciences, Sydney, Australia) using standard phosphoramidite chemistry in 1 µmol scale.
4.2. Cell Culture and In Vitro Cleavage Assay
U87MG (human malignant glioblastoma) cells were purchased from Cell Bank Australia (Sydney,
Australia). MDA-MB-231 cells (ATCC, Manassas, VA, USA) were kindly provided by A/Prof.
Stacey Edwards at the Queensland Berghofer Institute for Medical Research. All cells were cultured
at 37 ◦C in Dulbecco’s Modified Eagle Media (ThermoFisher, 12491-015, Melbourne, Australia)
supplemented with 10% FBS (Sigma, F8192, Sydney, Australia) and supplying 5% CO2/air.
A quantity of 20 µM mature miRNA was incubated with 100 nM antimiRzymes in the presence of
10 mM Mg2+ divalent cations for 30 min, 60 min, 120 min, and 180 min at 37 ◦C. The reactions were
terminated by adding 10 µL of formamide solutions. The products were then separated on a 15%
denaturing polyacrylamide gel and visualized using a Fusion FX Bilber Lourmat imager.
4.3. Transfection
Lipofectamine 3000 (L3000001, Invitrogen, Melbourne, Australia) was used according to the
manufacturer’s instructions. Briefly, cells were added on T25 cm2 flasks at a density of 2 × 105 cells/mL
in the indicated growth medium and propagated to 80% confluence at the time of transfection.
The antimiRzymes and control sequences were mixed with Lipofectamine 3000 with 1 µg nucleic acid
per 2 µL of Lipofectamine 3000 [TR/DNA ratio (w/w) = 2:1] and 1.5 µL of P3000 in the Opti-MEM
Reduced Serum Medium. The cells were then incubated at 37 ◦C for 24 h. All transfection assays were
carried out independently and with an untreated group and scrambled sequence group as controls.
4.4. Taqman qPCR to Measure the Expression of miR-21
Twenty-four hours after transfection of miR-21 targeting antimiRzymes, the total RNA of
different treatments was harvested, and cDNA was prepared by TaqMan™ MicroRNA Reverse
Transcription Kit (4427975, ThermoFisher, Melbourne, Australia) according to the supplier’s
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specifications. The gene-specific miR-21 primer is designed to match with the hsa-miR-21-5p sequence of
UAGCUUAUCAGACUGAUGUUGA. Real-time PCR was preformed using TaqMan Universal Master
Mix (4440040, ThermoFisher, Melbourne, Australia). on a C1000™ Thermal cycler, CFX96™ real-time
system (BioRad, Sydney, Australia) and programmed initially at 95 ◦C for 10 min, 95 ◦C for 15 s,
then 60 ◦C for 1 min, and repeated for a total of 40 cycles.
4.5. Statistical Analysis
All statistical analyses were performed using GraphPad Prism 3.03. An unpaired t test was
used for comparisons between two experimental groups. Unless otherwise indicated, all results were
averaged from biological triplicates and the values are reported as means ± SEM. A p-value of less
than 0.01 was considered statistically significant.
5. Conclusions
In summary, we investigated the potential of novel antimiRzymes for targeted inhibition of miR-21,
one of the most promising oncomiRs implicated in cancer pathology. A novel arm-loop-arm type
antimiRzyme RNV541 showed efficient inhibition of miR-21 in vitro and also in U87MG glioblastoma
cells and MDA-MB-231 triple negative breast cancer cells. Based on the high efficiency in glioblastoma
cells, targeted delivery of RNV541 was investigated using the previously reported transferrin receptor
targeting aptamer. The developed TfR aptamer-RNV541 chimera effectively delivered the RNV541
and showed efficient inhibition of miR-21 expression. Although we need to demonstrate the potential
of RNV541 in vivo, based on our very promising results, we firmly believe that this work could
serve as a proof-of-concept for the potential development of aptamer guided antimiRzymes towards
clinical development.
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